Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer. Yesterday, June 11, 2015, 92 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $332.85 to $17,302,509.00.
Highlighted Stocks Traded by Insiders:
Stifel Financial (SF) - FREE Research Report Estep Stephen Chad, who is Senior Vice President at Stifel Financial, sold 746 shares at $58.17 on June 11, 2015. Following this transaction, the Senior Vice President owned 904 shares meaning that the stake was reduced by 45.21% with the 746-share transaction.
The shares most recently traded at $59.02, up $0.85, or 1.44% since the insider transaction. Historical insider transactions for Stifel Financial go as follows:
- 4-Week # shares sold: 26,095
- 12-Week # shares sold: 26,095
- 24-Week # shares sold: 95,540
The average volume for Stifel Financial has been 416,000 shares per day over the past 30 days. Stifel Financial has a market cap of $4.0 billion and is part of the financial sector and financial services industry. Shares are up 16.88% year-to-date as of the close of trading on Thursday.
Stifel Financial Corp., a financial holding company, provides retail and institutional wealth management, and investment banking services primarily in the United States. The company has a P/E ratio of 26.0. Currently, there are 2 analysts who rate Stifel Financial a buy, no analysts rate it a sell, and 1 rates it a hold.
Exclusive Offer: Get the latest Stock Analysis on SF - FREE TheStreet Quant Ratings rates Stifel Financial as a
buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full
Stifel Financial Ratings Report from
TheStreet Quant Ratings now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Continental Resources (CLR) - FREE Research Report Mccain Ellis L, who is Director at Continental Resources, sold 6,666 shares at $46.51 on June 11, 2015. Following this transaction, the Director owned 47,200 shares meaning that the stake was reduced by 12.38% with the 6,666-share transaction.
The shares most recently traded at $46.19, down $0.32, or 0.7% since the insider transaction. Historical insider transactions for Continental Resources go as follows:
- 4-Week # shares bought: 139,621
- 4-Week # shares sold: 7,780
- 12-Week # shares bought: 139,621
- 12-Week # shares sold: 15,280
- 24-Week # shares bought: 139,621
- 24-Week # shares sold: 20,105
The average volume for Continental Resources has been 3.4 million shares per day over the past 30 days. Continental Resources has a market cap of $17.8 billion and is part of the basic materials sector and energy industry. Shares are up 21.87% year-to-date as of the close of trading on Thursday.
Continental Resources, Inc. explores, develops, and produces crude oil and natural gas properties in the north, south, and east regions of the United States. The company has a P/E ratio of 28.5. Currently, there are 9 analysts who rate Continental Resources a buy, 2 analysts rate it a sell, and 10 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on CLR - FREE TheStreet Quant Ratings rates Continental Resources as a
hold. Among the primary strengths of the company is its expanding profit margins over time. At the same time, however, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full
Continental Resources Ratings Report from
TheStreet Quant Ratings now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Opko Health (OPK) - FREE Research Report Baron Robert A, who is Director at Opko Health, bought 3,000 shares at $16.06 on June 11, 2015. Following this transaction, the Director owned 288,965 shares meaning that the stake was boosted by 1.05% with the 3,000-share transaction.
The shares most recently traded at $15.54, down $0.52, or 3.35% since the insider transaction. Historical insider transactions for Opko Health go as follows:
- 4-Week # shares bought: 10,000
- 4-Week # shares sold: 46,730
- 12-Week # shares bought: 10,000
- 12-Week # shares sold: 46,730
- 24-Week # shares bought: 10,000
- 24-Week # shares sold: 46,730
The average volume for Opko Health has been 3.7 million shares per day over the past 30 days. Opko Health has a market cap of $7.4 billion and is part of the health care sector and drugs industry. Shares are up 58.76% year-to-date as of the close of trading on Thursday.
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics. Currently, there are 3 analysts who rate Opko Health a buy, no analysts rate it a sell, and 1 rates it a hold.
Exclusive Offer: Get the latest Stock Analysis on OPK - FREE TheStreet Quant Ratings rates Opko Health as a
hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full
Opko Health Ratings Report from
TheStreet Quant Ratings now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. Data for this article provided by
Zacks Investment Research
